Trial
NCT03303794
0.25% Bupivacaine Versus a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Montefiore Medical Center
Collaborators
—
Condition
Anesthesia
Intervention
Exparel
Why stopped
Interim Analysis showed no significance
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-20